Q1 slump overshoots guidance; long-term capex intact but near-term stalled
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit one-offs (₹2.5 Cr write-off + ₹6 Cr job work); FY27 guidance cut from 20% to single-digit growth.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 revenue missed at -9.2% YoY (vs prior ≥20% FY27 guidance) and PAT crashed -34.8%, driven by monsoon-driven Pretilachlor volume collapse (-13%) and cost inflation. Management disclosed ₹8.5 Cr one-time charges, and inventory built speculatively now needs normalization. Long-term capex roadmap (Hamirpur ₹1,000 Cr, EU approval +₹30-40 Cr) remains credible but execution is 2-3 years out. Risk: sustained monsoon volatility or Hamirpur ramp delay could extend near-term pain.
₹256 Cr
Revenue · −9.2% YoY₹23 Cr
Reported PAT · −34.3% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Softer domestic demand, Pretilachlor hit by erratic rains
METVolume -13%, price +4%; domestic revenue ₹167 Cr vs ₹195 Cr YoY
One-time charges ₹8.5 Cr (₹2.5 Cr write-off + ₹6 Cr job work) impaired Q1 EBITDA
METEBITDA 15.4%, without one-offs would be ~18.5%; breakdown confirmed in Q&A
FY27 will achieve lower single-digit growth
MISSQ1 at -9.2%; prior call guided ≥20% FY27. Downgrade from 20% to <10%.
Hamirpur FY27 revenue ₹50-60 Cr from 2 new blocks
OVERSTATEDPrior implied ₹70-100 Cr; revised down. Not yet delivered; forward claim.
EU TEQ approval allows ₹30-40 Cr additional revenue from Nov 2026
UnverifiedApproval real, sales from Nov when customers add as source. Credible but forward.
Earnings quality
What changed since the last call
FY27 growth guidance slashed
DowngradePrior FY27 ≥20% growth; CFO now says 'lower single-digit growth.' Q1 at -9.2% makes recovery steep.
Hamirpur FY27 capex output cut
DowngradeImplied ₹70-100 Cr FY27 from Hamirpur; revised to ₹50-60 Cr. Only 2/10 blocks online; ramp slower than prior expectations.
EBITDA margin target moderated
DowngradePrior 18-20% guidance; Q1 delivered 15.4%. Management now targets 15-18% sustainable, below prior band.
Margin pressure narrative confirmed
NeutralOne-offs (₹8.5 Cr) + higher fuel/labor costs + volume loss all cited. Normalized margin ~18%, not 20%+.
Product diversification initiated
New3 new molecules in FY27 (fungicide already started, new herbicide at Sandila, herbicide MMP at Hamirpur). Reduces Pretilachlor dependence.
The Q&A
Analysts pressed hard on margin collapse (Yogansh), capex vs. guidance alignment (Kaushal), and Pretilachlor concentration (Karan). Management held, explaining one-offs and pivoting to long-term strategy. No evasions; tone cautious, not defensive. Score 7/10.
Margin collapse drivers — Yogansh Jeswani, Mittal Analytics
Answered₹2.5 Cr export receivable write-off + ₹6 Cr higher job work charges for herbicide intermediates. Fuel cost also up.
Volume vs. pricing split — Karan Shah, GeeCee
AnsweredVolume -13%, price +4%. Demand hit by erratic rains.
Product concentration risk — Karan Shah, GeeCee
PartialAdding 3 molecules in FY27 to diversify. Reduces dependence on any single product.
Hamirpur capex roadmap — Kaushal Sharma, Equinox
Answered8-10 blocks total; 2 blocks operational now, 1 more this year, 1 under construction. ₹100 Cr annual capex, 3-4 years to ₹1,000 Cr.
EU TEQ approval monetization — Saket Kapoor, Kapoor Co
AnsweredPrior ₹100 Cr annual sales; TEQ allows direct selling, adds ₹30-40 Cr. Sales from Nov; 1-2 months for customer approval.
New fungicide product viability — Yogansh Jeswani, Mittal Analytics
AnsweredIndia imports 4k-5k MT/yr; IPL targets 2k MT. Price ₹500-600/kg (₹10-12 Cr revenue). Capex ₹2-3 Cr for existing block balancing.
FY27 growth guidance — Karan Shah, GeeCee
PartialExpecting Q3/Q4 better, so lower single-digit growth this year.
Shalvis (subsidiary) contribution — Vidhi Shah, CR Kothari
Answered₹3 Cr, but netted off internally since RM purchased from IPL. ₹50-60 Cr expected FY27 from 2 blocks.
Capacity utilization — Kaushal Sharma, Equinox
Answered70%. Headroom for growth.
Receivables and working capital — Kaushal Sharma, Equinox
AnsweredReceivables stable at 120 days. Inventory up from 170 to 200 days due to lower Q1 sales; will normalize to 170 in Q3.
Guidance
FY27 lower single-digit growth (revised down from ≥20%)
MediumQ1 -9.2%; recovery depends on Q3/Q4 monsoon recovery. Capex ramp and new products not yet material.
Hamirpur FY27 ₹50-60 Cr revenue
Medium2 blocks operational/starting this year. Downward revision from prior ₹70-100 Cr hope. Not yet delivered.
EU approval ₹30-40 Cr incremental from Nov 2026
MediumReal approval; prior base ₹100 Cr. Ramp depends on customer approvals (1-2 months estimated).
EBITDA margin 15-18% sustainable (revised from 18-20%)
MediumQ1 delivered 15.4%. One-offs ₹8.5 Cr; normalized ~18.5%. Geopolitical/commodity headwinds flagged.
₹100 Cr annual capex across Sandila & Hamirpur
High₹70-100 Cr Hamirpur + ₹25-30 Cr Sandila. No debt; funded from cash flows. Multi-year commitment to ₹1,000 Cr Hamirpur.
Risks the call surfaced
Demand cyclicality
HighErratic rainfall delays sowing, depresses Pretilachlor (key herbicide for paddy). Q1 volume -13%. Risk: sustained erratic monsoon extends softness 2-3 quarters.
Product concentration
MediumPretilachlor (herbicide for paddy) is core product. Bad monsoon year → volumes collapse. No quantified percentage, but flagged in Q&A as structural vulnerability.
Execution risk
MediumHamirpur only 2/10 blocks live. FY27 revenue target ₹50-60 Cr (revised down from ₹70-100 Cr hope). ₹1,000 Cr target by FY30 requires flawless 3-4 year execution.
Pricing/competition
MediumChinese products undercutting on price. New fungicide import-replacement product (4k-5k MT market) targets ₹500-600/kg; Chinese likely lower. Margin erosion risk if capex efficiency or volumes don't scale.
Working capital
LowBuilt ₹6 Cr job work charges in anticipation of Q1 demand that didn't materialize. Inventory days 200 vs 170 normal. Expected to normalize Q3 when season begins.
Management
Score 7/10. Clear, transparent. One-offs disclosed (₹2.5 Cr write-off, ₹6 Cr job work). Roadmap quantified (8-10 blocks, capex plans). Some hedging on new product upside (not naming fungicide). No major evasions. Mixed. Q1 missed prior ≥20% FY27 guidance (now single-digit). Capex on track (₹100 Cr/yr). EU approval real. New products in early stage (not yet material). Inventory build was speculative mistake.
1 · Sep 2026
Monsoon season picks up; herbicide demand recovery expected (Pretilachlor ramp in Q2/Q3)
2 · Nov 2026
EU TEQ approval fungicide sales commence; ₹30-40 Cr incremental revenue target from direct customers
3 · FY27 end
New fungicide product (import replacement, 4k-5k MT market) ramps at Sandila; ₹10-12 Cr revenue potential
Risk: sustained monsoon volatility or Hamirpur ramp delay could extend near-term pain.
India Pesticides Q1 profit falls 35% YoY to ₹22.8 Cr as margins compress, revenue slips 8%
PAT -34.77% YoY · revenue -8.51% · margins compressing
₹251.76 Cr
-8.51% YoY
₹22.77 Cr
-34.77% YoY
8.9%
-3.4pp YoY
₹1.98
India Pesticides opened FY27 on a weak note: consolidated revenue from operations fell 8.5% YoY to ₹251.76 Cr (down 5.5% QoQ), and consolidated PAT dropped 34.8% YoY to ₹22.77 Cr (down 25.6% QoQ). Profit fell far faster than the topline because margins compressed sharply — net margin narrowed to ~9.0% from 12.3% a year ago and 11.3% last quarter, while operating margin slipped to roughly 14% versus the 18–20% band management guided on its last concall. The squeeze sits on the gross line: cost of materials consumed rose to ₹185.12 Cr even as revenue declined, so the print reflects both softer volumes/realisations and input-cost pressure rather than a one-off. The decline is not a base-effect illusion — the year-ago quarter carried a ₹2.29 Cr insurance-settlement gain in other income, and even adjusting that out, PAT is still down ~31% YoY. The standalone set tells the same story (PAT ₹23.07 Cr, −34.8% YoY; revenue ₹252.56 Cr, −8.3%), so there is no material divergence between the two bases.
Q1 FY-2027 vs prior quarters
The quarter contradicts management's confident November guidance of at least 20% standalone FY27 growth and 18–20% EBITDA margins — Q1 standalone revenue actually shrank ~8% YoY, leaving that full-year bar dependent on a steep H2 ramp, with the Shalvis subsidiary's promised ₹100 Cr contribution yet to show (the unlisted subs together posted a small ₹0.34 Cr net loss this quarter). No brokerage consensus is on record for this small-cap for the June quarter, and the company issued no accompanying management commentary with the numbers. The concurrent corporate news — EU and Morocco fungicide approvals flagged in July — is a forward revenue lever, not a Q1 driver. Separately, the filing discloses a ₹7.10 Cr income-tax demand from a block assessment (FY19–FY25), which the company believes is not tenable and has appealed; it is a contingent overhang, not charged to this quarter's P&L.
The stock went into the print at ₹154.15, down 5.7% over the past month of trading.
Management is confident in achieving its full-year FY26 revenue guidance of approximately INR 1,000 crores, supported by strong export recovery and a favorable domestic Rabi season. They reiterate their commitment to maintaining EBITDA margins within the 18%-20% range. For FY27, the company expects at least 20% standal
— This quarter: missed
W1
FY27 20% standalone-growth guidance vs Q1 standalone revenue down ~8% YoY — needs a sharp H2 recovery to hold
W2
EBITDA-margin path back toward the guided 18–20% band from Q1's ~14%
W3
Shalvis subsidiary ramp toward its promised ₹100 Cr FY27 contribution — subs still net-loss (₹0.34 Cr) this quarter
Clean digital filing, headers unambiguous. Consol PAT 22.77 (owners' share 22.74, NCI 0.03). Prior-year Q1 other income included a one-off Rs2.29 Cr insurance-claim settlement (Note 2) — inflates YoY base. Separate Rs7.10 Cr income-tax block-assessment demand disclosed (Note 4), under appeal, not in P&L.
Pretilachlor Rout Slashes FY27 Growth Guidance; Long-Term Capex Intact
Q1 revenue fell 8.5% as erratic monsoon crippled herbicide demand, and management cut full-year growth guidance from ≥20% to lower single-digit. One-time charges obscure the fact that normalized margins remained resilient, and capex plans for the ₹1,000 crore Hamirpur facility by FY30 are on track.
₹251.8 Cr
-8.5% YoY vs ≥20% FY27 guidance
₹22.8 Cr
-34.8% YoY
₹8.5 Cr
₹2.5 Cr write-off + ₹6 Cr job work
~18.5%
ex one-offs; reported 15.4%
How the Quarter Unfolded
India Pesticides guided ≥20% full-year FY27 growth on its prior call. Q1 delivered -8.5% revenue YoY, and management downgraded full-year guidance to 'lower single-digit growth'—a dramatic reversal. Net profit crashed -34.8% YoY, but the company disclosed ₹8.5 crore in one-time charges (a ₹2.5 crore export receivable write-off and ₹6 crore in job work for herbicide intermediates that didn't sell). Strip those out, and normalized EBITDA margin runs ~18.5%—not great, but defensible given the monsoon disruption.
The Demand Collapse That Triggered the Cut
The culprit was clear: Pretilachlor, the herbicide for paddy crops, fell 13% in volume as erratic monsoon rains delayed sowing across the country. Domestic revenue contracted to ₹167 crore from ₹195 crore a year ago. Management offered a 4% price increase to cushion the blow, but pricing power is limited when demand itself is collapsing. The company pivoted to long-term strategy on the call—committing to three new molecules (fungicide, herbicide import-replacement, herbicide multipurpose) and reaffirming capex plans for the Hamirpur facility (₹1,000 crore target by FY30, with 8–10 production blocks in the master plan but only 2 live today). The message: near-term pain, long-term ambition.
We have expected a good volume of herbicide. So we have converted a lot of raw material into intermediate, which will be consumed in next 2 to 3 months.
Softer domestic demand hit Pretilachlor volumes.
Volume -13%, price +4%. Domestic revenue ₹167 Cr vs ₹195 Cr YoY. Monsoon-driven.
Supported
₹8.5 Cr one-time charges impaired Q1 EBITDA.
₹2.5 Cr export receivable write-off + ₹6 Cr job work for unsold herbicide intermediates.
Supported
FY27 will achieve lower single-digit growth.
Q1 at -8.5% YoY; prior call guided ≥20% FY27. Guidance cut from 20% to <10%.
Contradicted
Hamirpur will deliver ₹50–60 Cr in FY27.
Prior implied ₹70–100 Cr. Only 2/10 blocks live; 1 more this year. Revised down.
Overstated (prior expectation)
EU TEQ approval opens ₹30–40 Cr incremental revenue from Nov 2026.
Approval is real; prior base ₹100 Cr. Sales depend on customer approvals (1–2 months estimated).
Unverified (credible, forward-looking)
What Changed on This Call
FY27 growth guidance: cut from ≥20% to lower single-digit
Hamirpur FY27 target: revised ₹50–60 Cr (down from ₹70–100 Cr implied)
EBITDA margin target: moderated to 15–18% (from 18–20% prior)
Product diversification: 3 new molecules in FY27 to reduce Pretilachlor concentration
EU TEQ approval: fungicide direct-market access, ₹30–40 Cr incremental revenue from Nov
How the Street Is Positioned
The market reacted sharply. The result was announced on Sat Aug 01 2026 at ₹154.15; the stock fell 3.62% on day 1, 5.35% by day 3, and 5.75% by day 5—a sell-off that held without reversal, signaling no bargain-hunting bounce. The stock now trades at ₹138.19 (as of 2026-08-18), down 29.83% from its all-time high of ₹196.93, below all major moving averages (SMA20 ₹146.63, SMA50 ₹154.53, SMA200 ₹160.86). RSI at 13.3 signals deep oversold conditions—but that hasn't arrested the selling pressure. Foreign institutional investors have fled dramatically: FII ownership collapsed from 2.78% (Q2 FY26) to 0.20% (Q1 FY27), a loss of 2.58 percentage points. This is the steepest FII exit in the company's recent history and signals a loss of institutional confidence in near-term recovery. Bulk block activity in the preceding months (May 2026) centered on NK Securities, likely algo rebalancing, with no promoter or insider activity flagged. The narrative: monsoon-hit demand is a known cyclical risk, but the guidance cut from ≥20% to single-digit growth suggests management confidence has eroded faster than the market foresaw.
The Bull-Bear Ledger
Capex roadmap (₹1,000 Cr Hamirpur by FY30) funded from ₹59 Cr cash, no debt
EU TEQ approval real; ₹30–40 Cr incremental revenue from Nov 2026
3 new molecules in FY27 reduce Pretilachlor concentration risk
Normalized EBITDA margin ~18.5% shows core business resilient if demand recovers
Capacity utilization 70%; ample headroom for growth
Q1 revenue down 8.5% vs ≥20% FY27 guidance; guidance cut signals eroded confidence
PAT crashed 34.8% YoY; normalized PAT still depressed
Hamirpur FY27 target revised down ₹20–40 Cr; only 2/10 blocks live
Monsoon volatility ongoing; Pretilachlor concentration persists until new products scale
FII exodus signals institutional confidence wavering; stock down 29.83% from ATH
Ranked Risks
Monsoon-driven demand cyclicality
HighErratic rainfall delayed sowing; Pretilachlor volume -13%. Bad monsoon in FY27 extends softness 2–3 quarters. Core demand risk, not inventory or pricing.
Hamirpur execution and capex ramp
HighOnly 2/10 blocks live; FY27 target revised ₹50–60 Cr (from ₹70–100 Cr implied). ₹1,000 Cr by FY30 requires flawless 3–4 year execution. Any delay cascades.
Product concentration on Pretilachlor
MediumPretilachlor is the dominant product. New molecules (fungicide, herbicide MMP) not yet scaled. Diversification is a 3–4 year journey; dependence persists.
Chinese competition and pricing pressure
MediumChinese agrochemical imports undercut on price. New fungicide import-replacement targets ₹500–600/kg; Chinese likely lower. Capex efficiency and volumes must offset.
Inventory normalization drag
LowBuilt ₹6 Cr job work charges for intermediates; inventory days 200 vs 170 normal. Expected to normalize Q3 as season begins; manageable working-capital headwind.
What to Watch Next
1 · Q2–Q3 monsoon recovery and sowing volume
If rainfall normalizes Sep onward, Pretilachlor demand should recover sharply. Track Q2 volume trends and management commentary on sowing intentions. A solid Q2 volume rebound would validate the 'cyclical trough' narrative; continued softness extends the pain.
2 · Hamirpur FY27 delivery and block ramp progress
Management guided ₹50–60 Cr FY27 revenue from Hamirpur. Track new block commissioning timelines (2nd block fungicide expected Q3–Q4 FY27) and actual revenue contribution. Any delay signals execution risk and pressures the ₹1,000 Cr by FY30 target.
3 · EU TEQ approval fungicide sales traction (from Nov 2026)
EU approval is real, but monetization depends on customer approvals (1–2 months estimated). Watch for order book visibility, customer confirmations, and ramp trajectory toward the ₹30–40 Cr incremental revenue target. This is the nearest concrete upside catalyst.
India Pesticides delivered a messy Q1: volume collapsed 13%, one-time charges inflated the damage, and management slashed full-year guidance from ≥20% growth to 'lower single-digit.' But the underlying story is more nuanced. Normalized EBITDA margin (~18.5%) held up, and the ₹1,000 crore Hamirpur capex roadmap by FY30 remains funded and on track. The real tension is between near-term consolidation (monsoon headwinds, Hamirpur ramp delays) and long-term scale ambition (3 new molecules, EU approval, ₹1,000 Cr facility).
The market's verdict has been swift and harsh: FII ownership collapsed from 2.78% to 0.20%, the stock fell -29.83% from its all-time high and has not bounced, and RSI is deeply oversold. This is less a 'buy the dip' moment and more a signal of institutional loss of confidence in near-term recovery. The guidance cut matters; it telegraphs that management itself is uncertain about the monsoon recovery trajectory.
Hold, not buy. The path to recovery depends on two things: monsoon normalization in Q2–Q3 (which would restore Pretilachlor demand) and Hamirpur execution staying on track (which would deliver the ₹50–60 Cr FY27 target and prove the ₹1,000 Cr vision is credible). Watch Q2 results for volume recovery signals and Hamirpur block commissioning progress. Until those are visible, the -30% drawdown and institutional exit are rational risk-off trades, not panic. The number to track from here is normalized EBITDA progression; if that stays at ~18–19% (before one-offs), the core business holds. If it drops further, the long-term thesis cracks.